Showing results (171-180 of 190) with videos related to

Sort By:
Pageof 19
Breast Cancer Research and Treatment|May 13, 2018
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trialCesar A Santa-Maria, Aditya Bardia, Amanda L Blackford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2015
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care GuidelineCarolyn D Runowicz, Corinne R Leach, N Lynn Henry, et al.
CA: a Cancer Journal for Clinicians|December 8, 2015
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care GuidelineCarolyn D Runowicz, Corinne R Leach, N Lynn Henry, et al.
JCO Precision Oncology|July 29, 2024
TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast CancerChristos Vaklavas, Cindy B Matsen, Zhengtao Chu, et al.
Journal of the National Cancer Institute|October 1, 2011
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working groupMitch Dowsett, Torsten O Nielsen, Roger A'Hern, et al.
Breast Cancer Research and Treatment|November 2, 2011
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancerAditya Bardia, Erin T Arieas, Zhe Zhang, et al.
JAMA Network Open|April 10, 2026
Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage CancerMeghna S Trivedi, Joseph M Unger, N Lynn Henry, et al.
Journal of the National Cancer Institute|October 21, 2022
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trialsMichael E Roth, Susan K Parsons, Patricia A Ganz, et al.
Pharmacogenomics|August 24, 2023
Effects of <i>CYP3A4</i> and <i>CYP2C9</i> genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226Delaney V Rutherford, Sarah Medley, Nicholas C Henderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without LapatinibLisa A Carey, Donald A Berry, Constance T Cirrincione, et al.
Pageof 19